Close Menu

Fred Hutchinson Cancer Research Center

Researchers have been using Nextstrain, which includes data for thousands of SARS-CoV-2 genomes, to study how the virus accrues mutations over time.

The researchers applied their approach to study the heterogeneity of immune cells and adapted a visualization tool to analyze the data.

Still Following It

Bloomberg writes that Fred Hutchinson Cancer Research Center's Trevor Bedford and his colleagues continue to use viral genomics to track SARS-CoV-2.

The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.

In Genome Biology this week: analysis of gut microbiomes from the Hispanic Community Health Study/Study of Latinos, collection of patient-derived tumor cells from gynecological cancers, and more.

The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.

The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.

In Genome Research this week: PeCanPIE platform for finding, annotating, and ranking pathogenic variants; commensal Escherichia coli analysis; and more.

Re-expression of DUX4, which is normally silenced in somatic tissues, appeared to stymie MHC class I-related immune activity in several solid cancer types.

Never smokers make up an increasing portion of lung cancer patients, and researchers are working to tease out their genetic and environmental risk.

Pages

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.